ACCESS AND SUPPORT
Learn about access and affordability support for appropriate patients
ICOTYDE™ (icotrokinra) 200 mg is indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.
IT’S UNBELIEVABLE
Pill not actual size.
See how
ICOTYDE works
Learn about the mechanism
behind the first and only targeted oral peptide1,2
Explore skin clearance data
Review ICOTYDE efficacy
results, including IGA 0/1, PASI 90, IGA 0, PASI 100, and mean PASI
ICONIC clinical trial program
Studied in 4 phase 3 clinical trials with 2500 patients1
1505 patients aged ≥18 years with plaque PsO1,3
Two phase 3, multicenter, randomized, double-blind, placebo-controlled and active comparator–controlled trials evaluating the efficacy and safety of ICOTYDE 200 mg orally once daily.
Eligibility:
- Moderate to severe plaque psoriasis defined as IGA ≥3, PASI ≥12, and BSA ≥10%
- Candidates for systemic therapy or phototherapy
Treatment periods:
- Patients randomized to placebo crossed over to ICOTYDE at Week 16
- Patients randomized to deucravacitinib crossed over to ICOTYDE at Week 24
- Patients received open-label ICOTYDE after Week 24 through Week 156
- Safety will be assessed through Week 160
684 patients aged ≥12 years with plaque PsO1,4
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ICOTYDE 200 mg orally once daily.
Eligibility:
- Moderate to severe plaque psoriasis defined as IGA ≥3, PASI ≥12, and BSA ≥10%
- Candidates for systemic therapy or phototherapy
Treatment periods:
- Patients randomized to placebo crossed over to ICOTYDE at Week 16
- Adults with a treatment response entered randomized withdrawal and retreatment from Week 24 to Week 52
- Patients received open-label ICOTYDE from Week 52 to Week 156
- Safety will be assessed through Week 160
311 patients aged ≥12 years with plaque PsO and high-impact site involvement1,5
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ICOTYDE 200 mg orally once daily.
Eligibility:
- Patients with plaque psoriasis who had a BSA ≥1%, IGA ≥2, and failed to respond to ≥1 topical therapies
- At least moderate psoriasis involving one of the following baseline conditions: ss-IGA ≥3, sPGA-G ≥3, and/or hf-PGA ≥3
- Candidates for systemic therapy or phototherapy
Treatment periods:
- Patients randomized to placebo crossed over to ICOTYDE at Week 16
- Efficacy will be evaluated through Week 156
- Safety will be assessed through Week 160
BSA, body surface area; hf-PGA, Physician’s Global Assessment of Hands and Feet; IGA, Investigator’s Global Assessment; IL-23R, interleukin-23 receptor; PASI, Psoriasis Area and Severity Index; PsO, psoriasis; sPGA-G, Static Physician’s Global Assessment of Genitalia; ss-IGA, Scalp-Specific Investigator’s Global Assessment.
References: 1. ICOTYDE [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Fourie AM, Cheng
X, Chang L, et al. JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust
IL-23 pathway inhibition upon oral dosing in rats and humans. Sci Rep. 2024;14(1):17515. doi:10.1038/
s41598-024-67371-5 3. Gold LS, Armstrong AW, Bissonnette R, et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025;406(10510):1363-1374. doi:10.1016/
S0140-6736(25)01576-4 4. Bissonnette R, Soung J, Hebert AA, et al. Oral icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med. 2025;393(18):1784-1795. doi:10.1056/NEJMoa2504187 5. Gooderham M, Lain E, Bissonnette R, et al. Targeted oral peptide icotrokinra for psoriasis involving high-impact sites. NEJM Evid. 2025:4(12):EVIDoa2500155. doi:10.1056/EVIDoa2500155